Wedbush analyst David Nierengarten says investors reacted negatively to Argenx’s (ARGX) Q1 earnings, but the current share price undervalues the opportunity in the “core” MG and CIDP franchises, and completely ignores the pipeline. The firm’s view is that Argenx can provide market-beating growth for the rest of the decade. The shares sold off after Q1 earnings, largely due to concerns about worsening gross-to-net as the PFS format caused a shift of Medicare patients from Part B to Part D and its higher deductible. But Wedbush thinks the selloff misses the growth potential for the PFS format, as it provides a significant step-up in patient convenience. The firm has an Outperform rating on the shares with a price target of $715.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Promising ALKIVIA Study Results Justify Buy Rating
- Argenx SE Announces AGM Results and Key Resolutions
- Argenx added to Best Ideas List at Wedbush
- Argenx pullback brings ‘attractive buying opportunity,’ says Citi
- Argenx Se: Strong Growth Prospects and Attractive Buying Opportunity Amid Vyvgart Expansion and Upcoming Catalysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue